Neuroendocrine Carcinoma Clinical Trial
Official title:
A Phase I Dose Escalation Study of Tolerability, Safety, Efficacy, and Pharmacokinetics of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by a Phase II Dose Expansion Study in Participants With Neuroendocrine Carcinoma.
This is a multicenter, open-label phase I/II study, divided into 2 parts: Part 1 involves a dose-escalation study of ZG006 in which the safety and tolerability of ZG006 in patients with advanced small cell lung cancer or neuroendocrine carcinoma are explored. Upon completion of Part 1, investigators and the sponsor will discuss and determine two recommended phase II doses (RP2D) based on safety, preliminary efficacy, and pharmacokinetic results for use in Part 2. Part 2 is a phase II dose-expansion study of ZG006, aiming to investigate the efficacy and safety of ZG006 in patients with Neuroendocrine Carcinoma.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01642251 -
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04069299 -
Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract
|
||
| Recruiting |
NCT04464122 -
Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)
|
||
| Recruiting |
NCT04325425 -
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
|
Phase 2 | |
| Completed |
NCT03834701 -
Endoscopic Ultrasound-guided RadioFrequency Ablation for the Treatment Pancreatic NeuroEndocrine Neoplasms
|
N/A | |
| Recruiting |
NCT03279614 -
Study to Evaluate the Efficiency of SOX as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05978284 -
Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine Carcinoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05076786 -
Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma
|
Phase 2 | |
| Completed |
NCT00388063 -
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT03901378 -
Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma
|
Phase 2 | |
| Recruiting |
NCT02970786 -
Phase I Trial: 68Ga-NODAGA-E(c[RGDyK])2 Positron Emission Tomography for Imaging Angiogenesis in Primary and Metastatic Tumor Lesions in Humans
|
Phase 1 | |
| Completed |
NCT00663429 -
Extension Study of the Safety and Efficacy of Atiprimod Treatment in Neuroendocrine Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05113355 -
Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm
|
Phase 2 | |
| Completed |
NCT03278405 -
Avelumab in G3 NEC
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03837977 -
Second-line Therapy for Patients With Progressive Poorly Differentiated Extra-pulmonary Neuroendocrine Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06372626 -
Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06333314 -
Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
|
Phase 2 | |
| Active, not recruiting |
NCT02687958 -
Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin
|
Phase 2 | |
| Completed |
NCT01121939 -
Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers
|
Phase 2 | |
| Recruiting |
NCT03168607 -
Study to Evaluate the Efficiency of FOLFIRI as Seconde-line Chemotherapy in Neuroendocrine Carcinoma
|
Phase 2 |